Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection

Table 1 Maternal characteristics of the control group and tenofovir disoproxil fumarate-treated group

Maternal characteristics	Control group (n= 24)	Treated group (n= 21)
Mean age (yr)	26.9 ± 2.9	28.2 ± 4.1
HBV DNA (IU/mL)	8.31 log	8.28 log
ALT levels (U/L )	52 (19-77)	56 (22-71)
Serum creatinine levels (mg/dL)	0.81 (0.6-1.0)	0.79 (0.6-0.98)
Compensated cirrhosis	0 (0%)	2 (10%)

HBV: Hepatitis B virus; ALT: Alanine aminotransferase.

Table 2 Maternal outcomes in the control group and tenofovir disoproxil fumarate-treated group n (%)

Maternal outcomes	Control group (n= 24)	Treated group (n= 21)
HBV DNA < 50 IU/mL	0 (0)	13 (62)
Normalized ALT (U/L)	15 (61)	17 (82)
Elevated creatinine kinase (> 165 mg/dL)	0 (0)	1 (4.7)
Spontaneous abortion	1 (4)	0 (0)
Gestational diabetes	0 (0)	1 (4.7)
Vaginitis	0 (0)	1 (4.7)
Arrhythmia	0 (0)	1 (4.7)
Anemia	0 (0)	1 (4.7)
Proteinuria	1 (4.2)	2 (10)

HBV: Hepatitis B virus; ALT: Alanine aminotransferase.

Table 3 Outcome of infants born to control mothers and tenofovir disoproxil fumarate-treated mothers n (%)

Infant characteristics and outcomes	Infants of control group mothers (n= 23)	Infants of treated group mothers (n= 21)
Birth weight < 2500 g	1 (4.3)	1 (4.7)
Immunophrophylaxis failure	2 (8.3)	0 (0)
Anti-hepatitis B surface levels > 100 mIU/mL	19 (82)	20 (95)
Hypothyroidism	0 (0)	0 (0)
Phenylketonuria	0 (0)	0 (0)
Congenital hearing loss	0 (0)	0 (0)